Ογ½ΆΚΣΖ΅

Skip to main content
Michael P. Teske
( out of 354 reviews )

Michael P. Teske, MD

Languages spoken: English

Clinical Locations

John A. Moran Eye Center

Salt Lake City
801-581-2352

Midvalley Health Center

Murray
801-581-2955
  • Michael P. Teske is the Director of Vitreoretinal Diseases and Surgery. Dr. Teske specializes in medical and surgical diseases of the retina and vitreous. His primary surgical interests include retinal detachment, proliferative vitreoretinopathy, diabetic retinopathy, retinopathy of prematurity, epiretinal membranes, macular holes and posterior segment trauma.

    Board Certification

    American Board of Ophthalmology
    National Board of Medical Examiners

    Patient Rating

    4.9 /5
    ( out of 354 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    October 29, 2024
    MORAN EYE CENTER

    Actually, this review is for those that work with Dr. Teske. He did not treat me this last visit. But I felt very comfortable with the doctor that did.

    October 29, 2024
    MORAN EYE CENTER

    I have continued to see Dr. Tusky over the last 12 years because I trust his care.

    October 10, 2024
    MORAN EYE CENTER

    I am very pleased to have Dr. Teske

    October 10, 2024
    MORAN EYE CENTER

    I make the trek from Pocatello to see him and his team because I couldn't ask for better care.

    September 29, 2024
    MORAN EYE CENTER

    I have been a patient of Dr. Teske's for many years. I trust him and his evaluation of ongoing treatment.

    September 28, 2024
    MORAN EYE CENTER

    Extremely knowledgeable and experienced retinal specialist. Highly recommended!

    September 27, 2024
    MORAN EYE CENTER

    I was sorry to hear thatDr Teske will retire nextJune.

    September 26, 2024
    MORAN EYE CENTER

    Just exceptional treatment. His knowledge is the best. I would recommend him to everyone for this care.

    September 26, 2024
    MORAN EYE CENTER

    Dr. Teske is a very competent, courteous and kind provider.

  • Michael P. Teske is the Director of Vitreoretinal Diseases and Surgery. Dr. Teske specializes in medical and surgical diseases of the retina and vitreous. His primary surgical interests include retinal detachment, proliferative vitreoretinopathy, diabetic retinopathy, retinopathy of prematurity, epiretinal membranes, macular holes and posterior segment trauma.

    Board Certification and Academic Information

    Academic Departments Ophthalmology & Visual Sciences -Primary
    Board Certification
    American Board of Ophthalmology
    National Board of Medical Examiners

    Education history

    Fellowship Retina/Vitreous - Wayne State Ογ½ΆΚΣΖ΅, Kresge Eye Institute Fellow
    Residency Ophthalmology - Ογ½ΆΚΣΖ΅ of Utah School of Medicine Resident
    Internship Internal Medicine - Ογ½ΆΚΣΖ΅ of Utah School of Medicine Intern
    Professional Medical Medicine - Ογ½ΆΚΣΖ΅ of California - Los Angeles M.D.
    Undergraduate Ογ½ΆΚΣΖ΅ of Notre Dame B.S.

    Selected Publications

    Journal Article

    1. Birch DG, Bernstein PS, Iannacone A, Pennesi ME, Lam BL, Heckenlively J, Csaky K, Hartnett ME, Winthrop KL, Jayasundera T, Hughbanks-Wheaton DK, Warner J, Yang P, Fish GE, Teske MP, Sklaver NK, Erker L, Chegarnov E, Smith T, Wahle A, VanVeldhuisen PC, McCormack J, Lindblad R, Bramer S, Rose S, Zilliox P, Francis PJ, Weleber RG (08/01/2018). Effect of Oral Valproic Acid vs. Placdbo for Vision Loss in Paients With Autosomal Dominant Retinitis Pigmentosa: A Randomized Phase 2 Multicenter Placebo-Controlled Clinical Trial. JAMA Ophthalmol, 136(8), 849-856.
    2. Birch DG, Bernstein PS, Iannacone A, Pennesi ME, Lam BL, Heckenlively J, Csaky K, Hartnett ME, Winthrop KL, Jayasundera T, Hughbanks-Wheaton DK, Warner J, Yang P, Fish GE, Teske MP, Sklaver NL, Erker L, Chegarnov E, Smith T, Wahle A, VanVeldhuisen PC, McCormack J, Lindblad R, Bramer S, Rose S, Zilliox P, Francis PJ, Weleber RG (2018). Effect of Oral Valproic Acid vs Placebo for Vision Loss in Patients With Autosomal Dominant Retinitis Pigmentosa: A Randomized Phase 2 Multicenter Placebo-Controlled Clinical Trial. JAMA Ophthalmol, 136(8), 849-856. ()
    3. Bell JE, Shulman JP, Swan RJ, Teske MP, Bernstein PS (2017). Intravitreal Versus Subretinal Tissue Plasminogen Activator Injection for Submacular Hemorrhage. Ophthalmic Surg Lasers Imaging Retina, 48(1), 26-32. ()